Bristol-Myers Squibb reports Q1 2026 results on May 5 with the stock down 4% on the month and short sellers quietly building pressure into the event.
Short interest has climbed sharply over the past week — up more than 11% in seven days — to reach 1.47% of the free float. That level is modest in absolute terms, but the pace of the move is notable. The short score has drifted higher through April to 30.4, placing the stock in roughly the 80th percentile on days-to-cover rank. Borrow remains easy: cost to borrow is a negligible 0.44%, and availability is extremely loose, meaning the lending market poses no friction for new short positions. Options positioning, by contrast, has actually eased. The put/call ratio of 0.90 is slightly below its 20-day average of 0.92 — leaning mildly bullish relative to recent norms, though well within a normal range. There is no defensive pile-on in the options market.
The analyst debate centres on pipeline durability versus revenue concentration risk. Bulls point to BMY's dominant positioning in immuno-oncology, a forward revenue profile the Street estimates at roughly $47 billion for full-year 2026, and a consensus mean target of $63.32 against Friday's close of $58.22 — implying roughly 8% upside even after recent price weakness. Piper Sandler and Barclays both carry Overweight ratings with targets at $75. BofA trimmed its target by $1 to $67 in early April while keeping a Buy — a reminder that the bull camp remains intact but is quietly dialling back ambition. Bears focus on the company's heavy reliance on the US market, which generates around 70% of sales, and on patent-cliff dynamics as competition intensifies around key franchises including Eliquis, whose near-term growth the company has already guided conservatively. The P/E of 9.7x looks inexpensive on the surface, with EV/EBITDA near 9x, but the multiple reflects the Street's caution about the revenue bridge into the back half of the decade.
The CFO, David Elkins, sold approximately $1.85 million in shares on April 1 — a routine look given the low trade-significance scores attached — while the CEO, Christopher Boerner, sold a smaller $279,000 position in March. The insider activity carries no net buying signal. On the institutional side, Vanguard and BlackRock together hold nearly 19% of shares, both marginally adding to positions as of the March quarter-end, providing a stable ownership base but no directional read-through for the print.
The dividend score ranks in the 99th percentile — an important anchor for holders, with the forward yield near 4.2% — which may explain why the stock has held a floor even as the quarter softened. Peer PFE gained 1.7% on Friday while BMY fell 3.9%, widening a divergence that has been building through the week. Tuesday's release will test whether BMY's Eliquis guidance and pipeline commentary justify closing that gap, or whether the Street's quiet skepticism was well-placed.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
